^
Association details:
| Biomarker: | RAD51 overexpression + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
167P - A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Published date:
10/16/2023
Excerpt:
Patients with HDC (P = 0.013) or TNFRSF1A (P = 0.0031) overexpression showed shorter PFS, whereas patients with RAD51 overexpression showed prolonged PFS (P = 0.049)….The immune-related gene model consisting of HDC, TNFRSF1A, and RAD51 could potentially predict the efficacy of EVE in premenopausal patients with HR+/HER2− ABC with endocrine resistance, which could help stratify responders to EVE and guide the choice of EVE in clinical practice.
Trial ID:
